Chapter 38: Independence (5)
Please visit frđđwđ.đ¸đđŞ website to read fastest update
âWe have a problem.â
Ji Kwang-Man went straight to Yoon Dae-Sung and told him everything that had happened until now. But there was no way Yoon Dae-Sung also had a solution either.
The fact that Young-Joon was going to be appointed as a director was already confirmed. It had leaked through an unknown route and was put on the editorial page of a major newspaper company. And in the meantime, A-Gen hadnât denied it once. It was because they liked the image of being an open-minded and progressive company that gave a dramatic promotion to a talented young employee and gave them a seat at the directorâs table. They couldnât push back the appointment now.
âSigh... Letâs go with it for now. I donât know where Doctor Ryu would get that kind of money, but even if he did, we could just stop him from creating an affiliate company at the board meeting. We donât have to propose the idea.â
The separation from a company and the creation of an affiliate company happened in two steps: it needed to be first brought up during a board meeting and then be approved in the shareholders' meeting. Young-Joon couldnât even attend the board meeting since he was an unregistered director. It wouldnât be a problem if it was held up in the board meeting and not passed over to the shareholders.
âBut I feel like heâs going to do something during the shareholders' meeting...â Ji Kwang-Man said.
âDo what?â
âI donât know, but Iâm anxious. What if he announces something about starting an affiliate company in front of the shareholders during the meeting?â
âAh, thatâs going too overboard with just a cure for glaucoma. The shareholders wonât react to that.â
Yoon Dae-Sung laughed and patted Ji Kwang-Man on the back.
âLetâs go with this for now.â
* * *
This was the largest A-Gen shareholders' meeting that was ever held; there were almost five times more people than usual. Mom-and-pop investors who had only invested small amounts in A-Gen had come to see Young-Joon. Among them, there were people who only had a single share as well.
There were three types of people at the shareholders' meeting. The majority of them were people who had benefited greatly from Young-Joon; they wanted to come see the golden calf.
The second group were people who were suffering from glaucoma or family members; they wanted to meet Young-Joon in person and show gratitude since he was able to greatly improve their quality of life.
The last group were people who had other neurological disorders or their families. There was no way they would be able to hear any good news in todayâs presentation since it wasnât like stem cell therapies were created in one day, but they were able to have hope as they had a base technology of induced pluripotent stem cells. Thatâs what they were here for.
â... And so, we would like to appoint Ryu Young-Joon as an in-house director. He was recommended by the board of directors, and the candidateâs brief history is as described in the shareholdersâ meeting notice,â CEO Yoon Dae-Sung said.
âDirector candidate Ryu Young-Joon has contributed greatly to the companyâs development by creating induced pluripotent stem cell and optic nerve differentiation technology and successfully finishing clinical trials for glaucoma. Are there any shareholders who object to this?â
âNo!â
âOf course, not!â
The shareholders shouted in their seats. Of course they had no objections as Young-Joon had increased company stocks by fifty percent in two days.
âThank you. Then, I declare that Ryu Young-Joonâs appointment as an in-house director has been approved as recommended by the board.â
Clap clap clap.
The crowd gave a round of applause. Young-Joon, who was sitting on one side of the stage, smiled as he saw someone wave their hand in the crowd. Cheon Ji-Myung, Bae Sun-Mi, Park Dong-Hyun, Jung Hae-Rim, and Koh Soon-Yeol were there. They had come to congratulate him on becoming appointed as a director.
Behind them were Choi Myung-Joon and Seo Yoon-Ju. He had come to show Young-Joon he was there, and she had come to spend time with Koh Soon-Yeol.
âTheyâre interesting people.â
Young-Joon chuckled as he looked at them.
It was now four oâclock in the afternoon. The meeting was coming to an end. At the end of the shareholdersâ meeting, A-Gen usually gave the appointed director some time for a short speech.
Young-Joon walked up to the podium and grabbed the mic.
âHello, shareholders,â Young-Joon said.
âIâm sure you have heard that I used induced pluripotent stem cells to differentiate somatic cells into optic nerve cells and succeeded in curing glaucoma with it in clinical trials.â
Young-Joon met eyes with each and every shareholder sitting in the hall.
âThe reason why I succeeded in this important research is not because I was outstanding, it was because a lot of people at A-Gen helped me. If I did it alone, I wouldnât have even been able to start clinical trials; I wouldnât have been approved.â
Young-Joonâs voice was full of confidence. Now, it was time for this meeting to be turned upside down.
âSo, my next research is something for A-Gen. While studying the history of the establishment and ideology of A-Gen, I came to know how the late Doctor Yoon Chul-Joong, the founder of A-Gen, spent his last days.â
Yoon Dae-Sung froze. It was something that had come up multiple times in his book.
His father, Yoon Chul-Joong, had suffered from Alzheimer type dementia. It was the humble end of the greatest intellectual who led Korea at that time; he spent his last days in loneliness, losing all his brilliant knowledge and wisdom.
From then on, Yoon Dae-Sungâs life goal was to cure Alzheimerâs.
Ji Kwang-Man sighed.
âHe managed to... Where did he get that kind of money anyway?â
Young-Joon went on.
âA-Bio will be an affiliate of A-Gen and will contribute greatly to their development. They will also be the pioneer of the international stem cell therapy market in the future. Also, as a director of A-Gen, I will do my best to promote A-Genâs rights, and I am also considering giving some of A-Bioâs shares to A-Gen to the extent where it will not affect my management rights. As such, the shareholders of A-Gen do not have to worry about the stocks of A-Gen falling due to the advancement of the affiliate company.â
âIs this already confirmed?â One of the reporters asked.
âIt will be on the agenda for the next board meeting. We will decide then how much of A-Bio shares A-Gen will take,â Young-Joon replied.
âI plan to confirm this notion by opening a special shareholdersâ meeting afterward. I am considering distributing some of my shares to the shareholders who exercise their voting right and approve of the establishment of A-Bio. The amount that will go to each person will be extremely small, even far below the decimal point, but within a few years, it will be huge enough to buy a condo.â
âWow...â
The shareholders looked at him differently. Again, there was commotion in the hall. Cameras flashed again.
The hot issue list on Naver was changing by the second from Ryu Young-Joon, to Alzheimerâs, and then to A-Bio.
âFuck...â
Ji Kwang-Man quietly cursed.
Young-Joon was stating that he was going to protect the current A-Gen stocks and give them the new companyâs stocks if they approve. On top of that, the new company was going to be built and run by Young-Joon and was going to be an affiliate of A-Gen. The shareholders would have to be insane to reject that notion. No, the shareholders looked like they were going to approve of it this instant.
Ji Kwang-Man turned around and looked at the in-house directors. Even some of the lab directors who were relatively less loyal to the CEO, such as Lab Five Director Joo Hwa-Young, looked like they were thinking about it.
âBut what was he talking about when he said it was on the agenda? Why havenât I heard anything?â In bewilderment, Gil Hyung-Joon asked Koh Yoo-Sung, who was sitting beside him.
âNicholas.â
Yoon Dae-Sung turned around to face the CTO.
âAre you helping Doctor Ryu?â
âI like Doctor Ryu, but Iâm not involved in this.â
âIt was me.â
Kim Young-Hoon raised his hand. He smiled in a smirking way.
He was someone that the SG Group, a major company in Korea that had six percent of shares, had put on the board. SG Group was also doing pharmaceuticals; it was called SG Pharmaceuticals.
Recently, Young-Joon sold his new flu drug patent to SG Pharmaceuticals for one hundred billion won. It had come into his bank account just yesterday, and he had invested twenty billion won as soon as he had it. He had actually gotten more than he thought; it was probably because he was worth a lot more after creating iPSCs, optic nerve treatment, and a glaucoma cure.
And in the process of selling the flu drug, Young-Joon got to know Kim Young-Hoon.
âTo be honest, the SG Group is hoping A-Gen abandons Doctor Ryu this time. Haha. Weâre thinking about scouting him to SG Pharmaceuticals. Doctor Ryu is insisting on staying at A-Gen since SG Pharmaceuticals is nowhere as big as A-Gen and has crappy infrastructure, but heâll go to SG Pharmaceuticals if you abandon him. The CEO of SG is also considering investing trillions of won into Doctor Ryu,â Kim Young-Hoon said.
âAnyway, we are going to put it on the board meeting agenda. Weâre registered directors of A-Gen, right? Although it seems like Doctor Ryu cannot participate in board meetings. And in this situation, youâre not going to be able to cut it off at the board meeting either. Why donât we set a date for the special shareholdersâ meeting?â
The faces of the people who supported Yoon Dae-Sung turned sour.
It would be beneficial for SG Pharmaceuticals just for Young-Joon to create an affiliate company and leave A-Gen, which was growing rapidly. SG Group didnât have a good relationship with A-Gen in the first place, so they didnât have a way to collaborate with Young-Joon even if they wanted to, but if Young-Joon became independent, it was possible.
Ji Kwang-Manâs hand trembled.
âWhy is the CEO or other people not getting this?â
There was something else that was seriously dangerous.
Young-Joon said that he was going to give a part of A-Bio to A-Gen in order to protect the shares that the A-Gen shareholders have. It was a plan to get approval for the separation of the affiliate company, but the situation was seriously twisted. Young-Joon was the one getting profit while the risk was taken on by A-Gen.
On the other hand, if A-Bio failed to begin due to A-Genâs rejection? Young-Joon would leave after as SG Group poured trillions of won into him, and A-Gen stock prices would plummet, causing irreversible damage to Yoon Dae-Sungâs management abilities.
If A-Gen didnât take A-Bioâs shares as he stated? Yoon Dae-Sungâs management abilities would also take a huge hit as people would say that they couldnât take it even when Young-Joon was handing it to them. This would also be irreversible damage.
What this meant was that whatever Young-Joon requested in turn for A-Bioâs shares, A-Gen had to give it to him to help start his affiliate company.
Young-Joon was so clever that he just may be the Devilâs child. Ji Kwang-Man imagined what that monster would request in turn for A-Bioâs shares in this situation. It was probably going to be an exchange of company shares, A-Gen for A-Bio.
âFxxk.â
Young-Joon already had four percent.
If, if the worst happened, Young-Joon could be the CEO of A-Gen and A-Bio.
1. Naver is a popular Korean search engine. It has a function that shows the frequently searched words real-time. ?
Visit and read more novel to help us update chapter quickly. Thank you so much!
Use arrow keys (or A / D) to PREV/NEXT chapter